Advanced stage disease
As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.
As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.
Professor Stefan Schreiber (Germany) discusses the future of therapies in IBD.
Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.
Inflammatory bowel disease can have a detrimental impact of health-related quality of life, and reducing the physical and psychological disease burden is an important therapeutic target. Patient-reported outcomes… read more.
To have a chance of preventing IBD clinicians need to be able to predict who is at risk, based on sensitive and selective risk factors. In a translational… read more.
IBD specialists have more treatment options than ever before; yet the optimal use of many agents, old as well as new, remains to be defined. A plenary session… read more.
Perianal fistulas remain a debilitating complication for CD patients, with high levels of morbidity and impact on quality of life. Several abstracts and posters at DDW 2018 addressed… read more.
This article summarises some of the key study updates presented at DDW 2018.
As a community IBD professionals are well aware of the need to raise the bar in terms of delivering quality care that maintains tight disease control and anticipates… read more.
Even with access to more potent and sophisticated drugs than ever before, IBD professionals still have a long way to go in optimising treatment and alleviating the long-term… read more.
Perianal fistula is a debilitating complication in CD which affects up to 50% of patients in the course of their disease…
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.